HeartSciences (Heart Test Laboratories, Inc.)
HeartSciences develops AI-enhanced ECG algorithms and the MyoVista Insights cloud platform plus MyoVista wavECG device to enable early detection of cardiovascular disease in hospitals and clinics; the company is pre-commercial and has announced an all-stock merger with Fortitude Mining Holdings.
- Company typePublic
- Founded2022
- HeadquartersSouthlake, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What HeartSciences (Heart Test Laboratories, Inc.) does
HeartSciences (Nasdaq: HSCS) is a medical technology company developing AI-enhanced electrocardiography (AI-ECG) solutions for early detection of cardiovascular disease. The company offers a two-product architecture: (1) MyoVista Insights, a device-agnostic, cloud-native ECG management platform that delivers AI algorithms over existing hospital ECG infrastructure, and (2) the MyoVista wavECG, a 12-lead resting ECG device with embedded AI. Underlying the platform is one of the largest commercial portfolios of AI-ECG algorithms disclosed, covering impaired cardiac relaxation, low and preserved ejection fraction, mitral valve regurgitation, aortic stenosis, pulmonary embolism, right ventricle dysfunction, hypertrophic cardiomyopathy, STEMI, and PVC-related cardiomyopathy, with reported external AUROC values ranging from 0.79 to 0.95 across indications. Proprietary Continuous Wavelet Transform signal processing and machine learning models are largely sourced from an IP licensing relationship with the Icahn School of Medicine at Mount Sinai, and the company holds 45+ granted patents.
The business model combines SaaS platform subscriptions, per-assessment AI-ECG fees (Medicare reimbursement of approximately $136 per assessment under APC 5734), algorithm marketplace economics (Bunkerhill Health's ECG-EF was the first third-party cleared algorithm on the marketplace), and hardware device sales. Customers include large integrated health systems, community hospitals, critical access hospitals, primary care practices, and academic institutions; named deployments include St. Vincent Health (CO), North Shore Health (MN) under the Cibolo Rural Health Networks umbrella, and the University of the West of England. Distribution is direct enterprise sales supplemented by the Epic Toolbox integration (HL7v2, SSO, SMART on FHIR). In June 2026 the company announced a definitive all-stock merger with Fortitude Mining Holdings (a Digital Currency Group-owned Zcash mining platform), expected to close H2 2026 under the ticker TUDE, with DCG projected to own ~95% of the combined entity and Fortitude's CEO leading the combined company.
The company remains at a very early commercial stage: no meaningful revenue was reported through fiscal Q3 2026 (ending January 2026), cumulative cash stood at approximately $3.4 million, shareholders' equity at approximately $2.7 million, and market capitalization at approximately $5.6 million as of June 2026. The CEO role is held by Andrew Simpson; the company has stated it will not replace the departed COO Mark Hilz. The pending merger with a non-healthcare digital asset mining entity represents a major strategic discontinuity for the underlying medtech franchise.
HeartSciences (Heart Test Laboratories, Inc.) firmographics
Firmographics- Name
- HeartSciences (Heart Test Laboratories, Inc.)
- Legal name
- Heart Test Laboratories, Inc.
- Website
- https://heartsciences.com
- Company type
- Public
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- HeartSciences develops AI-enhanced ECG algorithms and the MyoVista Insights cloud platform plus MyoVista wavECG device to enable early detection of cardiovascular disease in hospitals and clinics; the company is pre-commercial and has announced an all-stock merger with Fortitude Mining Holdings.
- Ownership category
- akta.pro rank
HeartSciences (Heart Test Laboratories, Inc.) industry classification
Industry- Product category
- AI-Enhanced Electrocardiography (Cardiac Diagnostics)
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)
- akta.pro secondary industries
- Electrophysiology Mapping & Ablation Systems (HLAHAFAD), Electrophysiology (Heart Rhythm) (HLAKABAC)
Keywords
Where HeartSciences (Heart Test Laboratories, Inc.) is headquartered
LocationHeadquarters
- HQ city
- Southlake
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
HeartSciences (Heart Test Laboratories, Inc.) business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- SaaS Platform Subscriptions: MyoVista Insights cloud platform delivered under a SaaS-based recurring revenue model where healthcare facilities pay subscription fees for access to AI-ECG algorithms and workflow management tools.
- Per-Assessment AI-ECG Fees: Medicare reimbursement at approximately $136 per assessment under APC 5734 for AI-ECG algorithm assessments performed with assistive AI-ECG algorithms on the MyoVista Insights platform.
- Algorithm Marketplace Commission: Platform hosting third-party FDA-cleared algorithms with recurring SaaS-based revenue model as algorithms are accessed through MyoVista Insights marketplace.
- MyoVista wavECG Device Sales: Hardware device sales of the MyoVista wavECG 12-lead resting ECG device with built-in AI-ECG technology.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | SaaS-based recurring revenue model for MyoVista Insights platform with per-assessment billing for AI-ECG algorithms. |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
HeartSciences (Heart Test Laboratories, Inc.) product offering
Product offeringCore offering
HeartSciences develops and sells AI-enhanced electrocardiography (AI-ECG) solutions, combining a cloud-native SaaS platform (MyoVista Insights) that delivers AI-ECG algorithms using existing ECG devices, with a proprietary 12-lead resting ECG hardware device (MyoVista wavECG) that has built-in AI-ECG capability. The company also operates an AI-ECG Algorithm Marketplace enabling third-party FDA-cleared cardiac algorithms to be hosted and distributed through its platform.
Product overview
HeartSciences offers a platform-plus-products architecture centered on AI-enhanced electrocardiography for cardiac disease detection. The core offerings consist of two integrated products: the MyoVista Insights cloud platform (a device-agnostic SaaS ECG management system with an AI-ECG Algorithm Marketplace) and the MyoVista wavECG hardware device (a 12-lead resting ECG with embedded AI). The company has developed one of the world's largest commercial portfolios of AI-ECG algorithms covering cardiovascular conditions including impaired cardiac relaxation, low ejection fraction, valvular diseases (mitral regurgitation, aortic stenosis), pulmonary embolism, right ventricle dysfunction, hypertrophic cardiomyopathy, STEMI, and PVC-related cardiomyopathy. The algorithms are delivered either through the MyoVista Insights cloud platform using existing ECG devices, or directly on the MyoVista wavECG hardware device. The AI-ECG Algorithm Marketplace enables third-party cleared algorithms to be hosted alongside HeartSciences' proprietary algorithms, creating a multi-algorithm ecosystem with recurring SaaS revenue.
Differentiator
Problem solved
Functional benefit
Brands
- MyoVista Insights: AI-ECG Cloud Platform - a device-agnostic, cloud-based ECG management system that delivers AI-ECG algorithms using existing ECG devices across hospitals and health systems.
- MyoVista wavECG
- MyoVista Insights AI-ECG Algorithm Marketplace
Products and services
- MyoVista Insights Cloud-native, device-agnostic ECG management platform that delivers FDA-cleared and proprietary AI-ECG algorithms using existing ECG devices across hospital and health systems. Supports HL7v2, single sign-on, and SMART on FHIR integration with EHRs, and is available through a SaaS-based recurring revenue model. Designed for healthcare facilities from large integrated health systems to community hospitals and critical access hospitals.
- MyoVista wavECG Device High-performance 12-lead resting ECG device with built-in AI-ECG technology that incorporates the Impaired Cardiac Relaxation algorithm using proprietary Continuous Wavelet Transform signal processing. Provides conventional ECG diagnostics plus AI-enabled cardiac dysfunction insights in a single test; portable with touchscreen interface, Wi-Fi enabled, and EMR-EHR capable.
- AI-ECG Algorithm Marketplace Marketplace within the MyoVista Insights platform that enables third-party FDA-cleared AI-ECG algorithms to be hosted and distributed to healthcare facilities. Operates on a SaaS-based recurring revenue model and targets healthcare facilities of all sizes across the United States.
Quantifiable outcome
- AI-ECG algorithm for low ejection fraction detection achieves AUROC of 0.94 in external validation with sensitivity of 0.87 and specificity of 0.85
- +4 more outcomes
Companies that use HeartSciences (Heart Test Laboratories, Inc.)
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
HeartSciences (Heart Test Laboratories, Inc.) technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability4 records
Feature12 records
HeartSciences (Heart Test Laboratories, Inc.) partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Bunkerhill HealthcoreBunkerhill Health's FDA-cleared ECG-EF algorithm for detecting reduced left ventricular ejection fraction became the first cleared AI-ECG algorithm available through MyoVista Insights AI-ECG Algorithm Marketplace. This partnership enables HeartSciences to offer third-party cleared algorithms on its platform while Bunkerhill gains distribution for their algorithm through HeartSciences' healthcare network.
- North Shore HealthcoreCommercial agreement with North Shore Health, a community hospital serving Cook County, Minnesota, to deploy the MyoVista Insights platform. This represents the first hospital deployment within Cibolo Rural Health Networks, demonstrating the platform's suitability for community healthcare settings.
- Cibolo Rural Health NetworkscoreCibolo Health previously selected MyoVista Insights as its endorsed ECG management platform for hospitals within its high-value networks, covering 127 independent hospitals. The North Shore Health agreement represents the first deployment following this endorsement.
- St. Vincent HealthcoreFirst SaaS revenues agreement with St. Vincent Health, a Critical Access Hospital serving Lake County, Colorado. This agreement marks HeartSciences' transition from early adopter installations to commercial SaaS deployments following full platform launch.
- Epic SystemscoreMyoVista Insights received Epic Toolbox designation for ECG Management System category, enabling integration with Epic's healthcare IT ecosystem. The platform supports HL7v2 workflows, single sign-on, and SMART on FHIR standards for seamless EHR integration.
- University of the West of England (UWE)minorUWE adopted HeartSciences' MyoVista Insights platform and MyoVista wavECG device as exclusive ECG technologies for educational purposes. The agreement establishes a Reference Center for ECG Education and Technology to train the next generation of cardiac scientists.
- Icahn School of Medicine at Mount SinaicoreHeartSciences licenses significant intellectual property from Mount Sinai for AI-ECG algorithm development. Multiple algorithms including Low Ejection Fraction, Mitral Valve Regurgitation, Aortic Stenosis, and others were developed using Mount Sinai datasets of hundreds of thousands of ECG-echo pairs.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
HeartSciences (Heart Test Laboratories, Inc.) competitors and assessment
Company assessmentDirect peers
- Eko Health: Eko Health develops AI-enabled digital stethoscopes and ECG algorithms (e.g., FDA-cleared SENSORA Cardiac Disease Detection) for cardiac screening in clinical and remote settings — a direct competitor in the AI-ECG space with both hardware devices and cloud-delivered algorithms.
- iRhythm Technologies: iRhythm's Zio ambulatory ECG monitoring service and AI-driven ECG analytics platform compete with HeartSciences in cardiac monitoring workflows, particularly for arrhythmia and structural heart detection via continuous or patch-based ECG.
- Anumana: Anumana, spun out of Mayo Clinic, develops AI-ECG algorithms for early detection of cardiac conditions (e.g., low ejection fraction, amyloidosis) — directly comparable as an algorithm-first AI-ECG company leveraging a leading academic medical center's clinical datasets, similar to HeartSciences' Mount Sinai relationship.
- AliveCor: AliveCor offers KardiaMobile consumer/clinical ECG devices and AI-based cardiac arrhythmia detection algorithms — overlapping directly with HeartSciences on AI-ECG hardware and software, though skewed more toward consumer/ambulatory use cases.
Emerging players
- Tempus AI: Tempus applies AI to multi-modal clinical data, including ECG-linked analytics, and represents a broader AI-driven clinical platform peer. It overlaps with HeartSciences on applying machine learning to cardiovascular data for diagnostic insight.
- Bunkerhill Health: Bunkerhill Health develops FDA-cleared ECG-based AI algorithms (e.g., ECG-EF for ejection fraction) and is HeartSciences' first marketplace partner on MyoVista Insights. It is both a partner and a competing algorithm developer that could in theory distribute through other ECG platforms.
Broad incumbents
- Preventice Solutions (Boston Scientific): Boston Scientific's Preventice body-worn cardiac monitoring portfolio (BodyGuardian) competes in ambulatory ECG and arrhythmia monitoring — adjacent to HeartSciences' AI-ECG screening use cases within cardiology workflows.
- Philips (IntelliSpace ECG): Philips IntelliSpace ECG is a widely deployed enterprise ECG management suite with growing AI capabilities. As a broad incumbent medtech player, Philips competes for the same large health-system ECG management budgets HeartSciences targets.
- GE HealthCare (MUSE): GE HealthCare's MUSE is one of the dominant enterprise ECG management systems installed in US hospitals. It is a broad incumbent whose installed base, salesforce, and capital give it a meaningful incumbent advantage as it layers AI capabilities onto its existing platform.
Others
- Carta Healthcare: Carta Healthcare focuses on AI-enabled clinical data abstraction and registry analytics for cardiology and other service lines. While not a direct AI-ECG competitor, it is an adjacent AI-for-cardiology peer whose ecosystem intersects with HeartSciences' hospital customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
HeartSciences (Heart Test Laboratories, Inc.) social profiles
Digital presenceHeartSciences (Heart Test Laboratories, Inc.) compliance and trust
Trust signalCompliance1 record
HeartSciences (Heart Test Laboratories, Inc.) financial estimates
Financial estimateRevenue estimate
Valuation estimate
HeartSciences (Heart Test Laboratories, Inc.) leadership team
Management profileNumber of profiles
Profiles14 records
HeartSciences (Heart Test Laboratories, Inc.) funding detail
Funding detailFunding overview
Funding rounds9 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HeartSciences (Heart Test Laboratories, Inc.) M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HeartSciences (Heart Test Laboratories, Inc.)
What does HeartSciences (Heart Test Laboratories, Inc.) do?
HeartSciences develops and sells AI-enhanced electrocardiography (AI-ECG) solutions, combining a cloud-native SaaS platform (MyoVista Insights) that delivers AI-ECG algorithms using existing ECG devices, with a proprietary 12-lead resting ECG hardware device (MyoVista wavECG) that has built-in AI-ECG capability. The company also operates an AI-ECG Algorithm Marketplace enabling third-party FDA-cleared cardiac algorithms to be hosted and distributed through its platform.
Is HeartSciences (Heart Test Laboratories, Inc.) a public or private company?
HeartSciences (Heart Test Laboratories, Inc.) is a public company. It is classified as public and is currently operating.
When was HeartSciences (Heart Test Laboratories, Inc.) founded?
HeartSciences (Heart Test Laboratories, Inc.) was founded in 2022. It employs 11 to 50 people.
Where is HeartSciences (Heart Test Laboratories, Inc.) based?
HeartSciences (Heart Test Laboratories, Inc.) is headquartered in Southlake, United States, in the North America region.
How does HeartSciences (Heart Test Laboratories, Inc.) make money?
Four revenue lines are on record. SaaS Platform Subscriptions are the primary driver. The others are per-Assessment AI-ECG Fees, algorithm Marketplace Commission and myoVista wavECG Device Sales.
Who are HeartSciences (Heart Test Laboratories, Inc.)'s main competitors?
Direct peers on record are Eko Health, iRhythm Technologies, Anumana and AliveCor. Emerging players are Tempus AI and Bunkerhill Health. Broad incumbents are Preventice Solutions (Boston Scientific), Philips (IntelliSpace ECG) and GE HealthCare (MUSE). Carta Healthcare is listed as an others.
Does HeartSciences (Heart Test Laboratories, Inc.) have an API?
No public API is recorded for HeartSciences (Heart Test Laboratories, Inc.).
What industry is HeartSciences (Heart Test Laboratories, Inc.) in?
HeartSciences (Heart Test Laboratories, Inc.)'s product category is AI-Enhanced Electrocardiography (Cardiac Diagnostics). Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLAHAFAD, Electrophysiology Mapping & Ablation Systems. Its NAICS code is 334510 and its SIC code is 3845.